Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars | Emerging Biosimilars | Global | 2019

Login to access report north_east
Contact sales account_box

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.

Questions Answered in This Report:

  • How many biosimilar candidates are currently undergoing phase I or III clinical development in a particular region?
  • Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
  • Which are the top 10 biosimilars developers by number of clinical stage candidates?
  • When is the expected launch date for late stage pipeline candidates in the seven major markets?
  • What is the level of competition expected for a brand, globally and by region/country?

Scope:

  • Markets covered: Global
  • Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.

Mentioned in This Report:

Key Companies Mentioned

  • Amgen
  • Biocad
  • Biocon
  • Celltrion
  • Daiichi Sankyo
  • Dr. Reddy’s
  • Fresenius Kabi
  • Gedeon Richter
  • Intas
  • Merck & Co
  • Mylan
  • Pfizer
  • Samsung Bioepis
  • Sandoz
  • Stada

Key Drugs Mentioned

  • Aranesp
  • Avastin
  • Enbrel
  • Erbitux
  • Forteo
  • Herceptin
  • Humira
  • Lantus
  • Neulasta
  • Neupogen
  • Remicade
  • Rituxan / MabThera
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
north_east
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
north_east
Report
Biosimilars – Current Treatment – Immunology
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
north_east
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
north_east
Report
Biosimilars – Forecast – Immunology
In 2023, sales of branded biologics in immunology exceeded $64 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east